To Succeed in Crowded Market, Diabetes Manufacturers Beginning Key Launch Tactics Earlier, Study Says
CHAPEL HILL, N.C. – September 27, 2011 – A rapidly changing – and highly competitive – Diabetes marketplace demands that pharma and biotech companies be vigilant and ready to adapt new technologies and new therapeutic approaches when launching a new product.
To ensure successful market entry, Diabetes launch teams are scrutinizing their strategies and tactics to support early market education, which has become a critical launch factor.
According to primary research from Best Practices LLC, Diabetes launch teams introduce education to Primary Care Physicians and Nurse Practitioners somewhat earlier – at two years prior to actually launch – than companies generally do for drugs competing in other therapeutic areas. This likely reflects the importance of PCPs and Nurses in the treatment of Diabetes.
Furthermore, companies signaled Phase II as the kickoff point for most of their thought leader engagement efforts and services, while some companies with strong pipelines and a long-standing commitment to Diabetes are even initiating thought leader services as early as the pre-clinical research phase.
“Shaping the Marketplace to Support Successful Diabetes Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers,” the report from which this data is culled, delivers a wealth of benchmark metrics on the most effective physician, payer and patient education practices conducted from clinical development through launch.
The 160-page report contains almost 500 metrics to help inform launch leaders in the Diabetes area on the most effective type and timing of market education practices during the full development cycle.
The research - which includes both a specialized Diabetes segment as well as a broader benchmark class of participating companies from across all therapeutic areas - attracted 34 executives and managers from 26 leading pharmaceutical, biotech and medical device companies, including 13 of the Top 20 pharmaceutical companies.
Executives and managers from throughout the biopharma landscape – and in the Diabetes therapeutic area in particular – have found this research invaluable in comparing their own market education tactics and strategies with those of leading organizations.
To learn more about the study, download a complimentary summary at http://www.best-in-class.com/rr1121.htm.
For more information, contact Cameron Tew, Executive Director of Research and Publishing at Best Practices, LLC at (919) 767-9246 or email@example.com.
BEST PRACTICES, LLC conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 of the top 50 pharmaceutical companies.